Skip to main content
PHAT
NASDAQ Life Sciences

Phathom Pharmaceuticals Q1收入增长超过两倍，强劲的VOQUEZNA销售超出预期

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$12.3
Mkt Cap
$935.687M
52W Low
$2.21
52W High
$18.31
Market data snapshot near publication time

summarizeSummary

Phathom Pharmaceuticals公布了强劲的第一季度财报，其收入增长超过两倍，达到5820万美元，超出了分析师5703万美元的预期。该公司还超出了调整后每股收益预期，报告的数字为-0.18美元，而预期的数字为-0.32美元。这一强劲的表现主要是由VOQUEZNA处方年同比增长115%和经营费用减少40%驱动的。这些结果强化了公司的正轨迹，符合其之前的10-K预测，即到2026年第三季度实现经营盈利，并保持2026年的净收入指导3200万美元至3450万美元。这种显著的运营改善和强劲的产品增长是对股票的重要利好，表明其商业战略的有效执行。交易者现在将关注公司实现第三季度盈利目标和持续VOQUEZNA增长的进展。

在该公告发布时，PHAT的交易价格为$12.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.4亿。 52周交易区间为$2.21至$18.31。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed PHAT - Latest Insights

PHAT
Apr 30, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
8
Phathom Pharmaceuticals Q1 Revenue More Than Doubles, Beats Estimates on Strong VOQUEZNA Sales
Sentiment: Positive
View Wiseek Article
PHAT
Apr 30, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Phathom Pharmaceuticals Reports Strong Q1 2026 Results with Doubled Revenue, Reduced Losses, and Improved Liquidity
Sentiment: Positive
View Wiseek Article
PHAT
Apr 30, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Phathom Pharmaceuticals Reports Strong Q1 Results, Maintains FY26 Guidance, and Accelerates Clinical Trial Readout
Sentiment: Positive
View Wiseek Article
PHAT
Feb 26, 2026, 7:06 AM EST
Filing Type: 10-K
Importance Score:
9
Phathom Pharmaceuticals Reports Strong 2025 Revenue Growth, Refinances Debt, and Extends Liquidity
Sentiment: Positive
View Wiseek Article
PHAT
Feb 26, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Phathom Pharmaceuticals Reports Strong Q4 & FY25 Results, Guides for 2026 Profitability, and Strengthens Capital Structure
Sentiment: Positive
View Wiseek Article
PHAT
Jan 08, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Phathom Pharmaceuticals Prices $130M Public Offering at Premium to Market
Sentiment: Neutral
View Wiseek Article
PHAT
Jan 08, 2026, 4:01 PM EST
Filing Type: 424B5
Importance Score:
8
Phathom Pharmaceuticals Announces $122M Public Offering of Common Stock and Pre-Funded Warrants
Sentiment: Neutral
View Wiseek Article
PHAT
Jan 07, 2026, 4:34 PM EST
Filing Type: 424B5
Importance Score:
7
Phathom Pharmaceuticals Announces Dilutive Equity Offering Including Common Stock and Pre-Funded Warrants
Sentiment: Negative
View Wiseek Article
PHAT
Jan 07, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
8
Phathom Pharmaceuticals Reports Strong Preliminary 2025 Results, Targets H2 2026 Operating Profitability
Sentiment: Positive
View Wiseek Article
PHAT
Jan 07, 2026, 4:01 PM EST
Filing Type: S-3ASR
Importance Score:
8
Major Investor Frazier Life Sciences Files to Liquidate Entire 8.2% Stake Near 52-Week Highs
Sentiment: Negative
View Wiseek Article